Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Dermatomyositis
•
Dermatology
•
Drug Eruptions
•
SLE
What laboratory studies do you routinely order when evaluating a patient with interface dermatitis on biopsy?
Related Questions
What specific historical questions do you prioritize when evaluating hair loss to identify features suggestive of autoimmune or connective tissue disorders?
Do you check IgA levels before starting IVIG for other autoimmune conditions?
How do you counsel patients with dermatomyositis on sun protection?
Do you reduce the dose of hydroxychloroquine in patients with skin graying if they are not particularly bothered by this side effect?
What is the most appropriate next step in management for a patient with dermatomyositis who is maintained on methotrexate 25 mg weekly but develops disease flare when prednisone is tapered below 10 mg daily and is unable to receive IVIG?
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
Which serologic tests are most helpful when evaluating for suspected drug-induced lupus?
What are your vaccine recommendations while patients are on biologics?
What is your approach to a patient with generalized morphea, no systemic involvement but a positive RNA Polymerase III?
How do you approach management of patients with RA who have paradoxical eczematous reaction while on TNF inhibitor?
